BRPI0811210B1 - Agente de formação de imagem, composição farmacêutica, método de preparação de um agente de formação de imagem, e, kit para a preparação da composição farmacêutica - Google Patents

Agente de formação de imagem, composição farmacêutica, método de preparação de um agente de formação de imagem, e, kit para a preparação da composição farmacêutica Download PDF

Info

Publication number
BRPI0811210B1
BRPI0811210B1 BRPI0811210-0A BRPI0811210A BRPI0811210B1 BR PI0811210 B1 BRPI0811210 B1 BR PI0811210B1 BR PI0811210 A BRPI0811210 A BR PI0811210A BR PI0811210 B1 BRPI0811210 B1 BR PI0811210B1
Authority
BR
Brazil
Prior art keywords
cmbp
gly
peptide
imaging agent
glu
Prior art date
Application number
BRPI0811210-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Edvin Wilhelm Johannesen
Alan Cuthbertson
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0709441A external-priority patent/GB0709441D0/en
Priority claimed from GB0715682A external-priority patent/GB0715682D0/en
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Publication of BRPI0811210A2 publication Critical patent/BRPI0811210A2/pt
Publication of BRPI0811210B1 publication Critical patent/BRPI0811210B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4842—Monitoring progression or stage of a disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Solid State Image Pick-Up Elements (AREA)
BRPI0811210-0A 2007-05-16 2008-05-16 Agente de formação de imagem, composição farmacêutica, método de preparação de um agente de formação de imagem, e, kit para a preparação da composição farmacêutica BRPI0811210B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0709441.0 2007-05-16
GB0709441A GB0709441D0 (en) 2007-05-16 2007-05-16 Peptide imaging agents
GB0715682A GB0715682D0 (en) 2007-08-13 2007-08-13 Peptide imaging agents
GB0715682.1 2007-08-13
PCT/GB2008/001696 WO2008139207A2 (en) 2007-05-16 2008-05-16 Labelled hgf binding peptides for imaging

Publications (2)

Publication Number Publication Date
BRPI0811210A2 BRPI0811210A2 (pt) 2014-11-11
BRPI0811210B1 true BRPI0811210B1 (pt) 2021-11-09

Family

ID=39743846

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0811210-0A BRPI0811210B1 (pt) 2007-05-16 2008-05-16 Agente de formação de imagem, composição farmacêutica, método de preparação de um agente de formação de imagem, e, kit para a preparação da composição farmacêutica

Country Status (17)

Country Link
US (1) US8529874B2 (enExample)
EP (1) EP2146749B1 (enExample)
JP (1) JP2010526859A (enExample)
KR (2) KR101578225B1 (enExample)
CN (1) CN101848734B (enExample)
AT (1) ATE551073T1 (enExample)
AU (1) AU2008249821B2 (enExample)
BR (1) BRPI0811210B1 (enExample)
CA (1) CA2685553C (enExample)
ES (1) ES2385066T3 (enExample)
IL (1) IL201778A0 (enExample)
MX (1) MX2009012386A (enExample)
NZ (1) NZ581160A (enExample)
PL (1) PL2146749T3 (enExample)
RU (2) RU2475266C2 (enExample)
WO (1) WO2008139207A2 (enExample)
ZA (1) ZA200908016B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0811588A2 (pt) * 2007-05-16 2014-10-21 Ge Healthcare As Agente de formação de imagem, composição farmacêutica, kit para a preparação da mesma, conjugado, corante de cianina, e, métodos de formação de imagem óptica in vivo do corpo de um mamífero e de detecção, avaliação do estágio, diagnóstico, monitoração da progressão da doença ou monitoração do tratamento de um estado de doença do corpo de um mamífero
GB0718967D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Peptide imaging agents
GB0918321D0 (en) 2009-10-20 2009-12-02 Ge Healthcare As Cyclic peptide synthesis
GB201010878D0 (en) 2010-06-29 2010-08-11 Ge Healthcare As Dye compositiion and dye syntheses
WO2012001063A1 (en) * 2010-06-29 2012-01-05 Ge Healthcare As Dye compositions and dye syntheses
GB201013808D0 (en) 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
WO2012048063A2 (en) * 2010-10-06 2012-04-12 Emd Millipore Corporation Cyanine compounds, conjugates and method of use
CA2828810A1 (en) 2011-03-01 2012-09-07 Ge Healthcare Limited Radiolabelled octreotate analogues as pet tracers
GB201103696D0 (en) 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
DE102011118029A1 (de) * 2011-06-20 2012-12-20 Universität Leipzig Modifizierte antibiotische Peptide mit variabler systemischer Freisetzung
GB201116733D0 (en) 2011-09-28 2011-11-09 Ge Healthcare As Peptide margin imaging agents
GB201116862D0 (en) 2011-09-30 2011-11-09 Ge Healthcare As Infusion imaging method
GB201121914D0 (en) * 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
US10046068B2 (en) * 2013-03-15 2018-08-14 Arizona Board Of Regents On Behalf Of Arizona State University Saccharide conjugates
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
CN105111773B (zh) * 2015-08-19 2017-06-27 大连理工大学 一类氨基菁类荧光染料及其制备方法和应用
GB201804835D0 (en) * 2018-03-26 2018-05-09 Ge Healthcare As Formulation and method of preparation
CN112129736B (zh) * 2020-09-22 2022-08-02 四川大学华西医院 粘蛋白和循环肿瘤细胞的均相可视化/荧光poct检测方法
EP4352167A1 (en) * 2021-06-07 2024-04-17 SurgVision GmbH Stable liquid phantom for near-infrared fluorescence verification
TW202404643A (zh) 2022-04-20 2024-02-01 大陸商同宜醫藥（蘇州）有限公司 化合物及用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2258776A1 (en) * 2002-05-10 2010-12-08 Carnegie Mellon University Fluorescent cyanine dyes containing functional groups
GB0223249D0 (en) * 2002-10-08 2002-11-13 Amersham Plc Improved imaging agents
EP1594551A2 (en) * 2003-02-19 2005-11-16 Sicel Technologies, Inc. In vivo fluorescence sensors, systems, and related methods operating in conjunction with fluorescent analytes
PT2949658T (pt) * 2003-03-03 2018-10-18 Bracco Suisse Sa Péptidos que ligam especificamente o recetor de hgf (cmet) e utilizações dos mesmos
NO20034350D0 (no) * 2003-09-29 2003-09-29 Amersham Health As Optisk avbilding av kolorektal kreft
US7750163B2 (en) * 2003-10-31 2010-07-06 GE Healthcare U.K. Limited Cyanine dye labelling reagents
US7785566B2 (en) 2003-11-06 2010-08-31 Ge Healthcare, Inc. Pharmaceutical compounds
NO20035682D0 (no) 2003-12-18 2003-12-18 Amersham Health As Optisk avbildning av ösofagkreft og Barretts ösofag
WO2006073314A1 (en) * 2005-01-06 2006-07-13 Ge Healthcare As Optical imaging
US8053415B2 (en) * 2005-01-21 2011-11-08 Washington University In St. Louis Compounds having RD targeting motifs
GB0502277D0 (en) 2005-02-04 2005-03-09 Amersham Plc Novel imaging agents
EP1877428B1 (en) * 2005-04-22 2011-03-16 University of Washington Cyanine- chlorotoxin conjugate and method for intra-operative visualization of cancer
NO20053354D0 (no) 2005-07-11 2005-07-11 Amersham Health As Optical imaging contrast agent.

Also Published As

Publication number Publication date
RU2475266C2 (ru) 2013-02-20
CA2685553C (en) 2017-03-28
WO2008139207A3 (en) 2009-02-26
BRPI0811210A2 (pt) 2014-11-11
KR20150017387A (ko) 2015-02-16
KR101578225B1 (ko) 2015-12-17
EP2146749A2 (en) 2010-01-27
US8529874B2 (en) 2013-09-10
CA2685553A1 (en) 2008-11-20
RU2009140475A (ru) 2011-06-27
WO2008139207A2 (en) 2008-11-20
NZ581160A (en) 2012-05-25
AU2008249821A1 (en) 2008-11-20
ZA200908016B (en) 2012-04-25
CN101848734B (zh) 2013-08-28
KR20100016543A (ko) 2010-02-12
RU2473361C9 (ru) 2013-06-20
MX2009012386A (es) 2009-12-03
ATE551073T1 (de) 2012-04-15
AU2008249821B2 (en) 2013-08-22
PL2146749T3 (pl) 2012-09-28
CN101848734A (zh) 2010-09-29
US20100150843A1 (en) 2010-06-17
RU2009140478A (ru) 2011-06-27
RU2473361C2 (ru) 2013-01-27
EP2146749B1 (en) 2012-03-28
IL201778A0 (en) 2010-06-16
ES2385066T3 (es) 2012-07-17
JP2010526859A (ja) 2010-08-05

Similar Documents

Publication Publication Date Title
US8529874B2 (en) Peptide imaging agents
US8431111B2 (en) Peptide imaging agents
RU2484111C2 (ru) Агенты для оптической визуализации
ES2923148T3 (es) Formulación y método de preparación
US20100303727A1 (en) Optical imaging agents
US20110268660A1 (en) Method for detecting dysplasia
WO2013045662A1 (en) Peptide margin imaging agents
WO2013045650A2 (en) Infusion imaging method
HK1148476A (en) Labelled hgf binding peptides for imaging

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 49/00 (2006.01), A61B 5/00 (2006.01)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/05/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]

Free format text: RETIFICA-SE O DEFERIMENTO NOTIFICADO NA RPI NO 2636 DE 13/07/2021.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2827 DE 11-03-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.